Soares Márcio, Salluh Jorge I F
Instituto Nacional de Câncer - INCA, Centro de Tratamento Intensivo, 10o Andar, Pça. Cruz Vermelha, 23, 20230-130, Rio de Janeiro, RJ, Brazil.
Intensive Care Med. 2006 Nov;32(11):1839-44. doi: 10.1007/s00134-006-0374-4. Epub 2006 Sep 15.
To validate the SAPS 3 admission prognostic model in patients with cancer admitted to the intensive care unit (ICU).
Cohort study.
Ten-bed medical-surgical oncologic ICU.
Nine hundred and fifty-two consecutive patients admitted over a 3-year period.
None.
Data were prospectively collected at admission of ICU. SAPS II and SAPS 3 scores with respective estimated mortality rates were calculated. Discrimination was assessed by area under receiver operating characteristic (AUROC) curves and calibration by Hosmer-Lemeshow goodness-of-fit test. The mean age was 58.3+/-23.1 years; there were 471 (49%) scheduled surgical, 348 (37%) medical and 133 (14%) emergency surgical patients. ICU and hospital mortality rates were 24.6% and 33.5%, respectively. The mean SAPS 3 and SAPS II scores were 52.3+/-18.5 points and 35.3+/-20.7 points, respectively. All prognostic models showed excellent discrimination (AUROC>or=0.8). The calibration of SAPS II was poor (p<0.001). However, the calibration of standard SAPS 3 and its customized equation for Central and South American (CSA) countries were appropriate (p>0.05). SAPS II and standard SAPS 3 prognostic models tended somewhat to underestimate the observed mortality (SMR>1). However, when the customized equation was used, the estimated mortality was closer to the observed mortality [SMR=0.95 (95% CI=0.84-1.07)]. Similar results were observed when scheduled surgical patients were excluded.
The SAPS 3 admission prognostic model at ICU admission, in particular its customized equation for CSA, was accurate in our cohort of critically ill patients with cancer.
验证重症监护病房(ICU)收治的癌症患者的序贯器官衰竭评估(SAPS)3入院预后模型。
队列研究。
拥有10张床位的内科-外科肿瘤ICU。
3年期间连续收治的952例患者。
无。
在ICU入院时前瞻性收集数据。计算SAPS II和SAPS 3评分以及各自的估计死亡率。通过受试者操作特征曲线下面积(AUROC)评估辨别力,通过Hosmer-Lemeshow拟合优度检验评估校准。平均年龄为58.3±23.1岁;有471例(49%)择期手术患者、348例(37%)内科患者和133例(14%)急诊手术患者。ICU死亡率和医院死亡率分别为24.6%和33.5%。SAPS 3和SAPS II的平均评分分别为52.3±18.5分和35.3±20.7分。所有预后模型均显示出良好的辨别力(AUROC≥0.8)。SAPS II的校准较差(p<0.001)。然而,标准SAPS 3及其针对中美洲和南美洲(CSA)国家的定制方程校准合适(p>0.05)。SAPS II和标准SAPS 3预后模型在一定程度上倾向于低估观察到的死亡率(标准化死亡比>1)。然而,使用定制方程时,估计死亡率更接近观察到的死亡率[标准化死亡比=0.95(95%CI=0.84-1.07)]。排除择期手术患者时观察到类似结果。
ICU入院时的SAPS 3入院预后模型,尤其是其针对CSA的定制方程,在我们的重症癌症患者队列中是准确的。